Financial news, mergers and acquisitions, partnerships, and alliances.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.
The firm is focused on developing oncology drugs that target mutations in the RAS pathway.
The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.
The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.